CO11 INDIRECT TREATMENT COMPARISON OF MARSTACIMAB VERSUS FITUSIRAN ANTITHROMBIN-BASED DOSE REGIMEN AMONG INDIVIDUALS WITH HEMOPHILIA A/B, WITHOUT INHIBITORS, WHO PREVIOUSLY RECEIVED ON-DEMAND THERAPY

IF 1.9 Q3 HEALTH CARE SCIENCES & SERVICES

Value in health regional issues Pub Date : 2026-10-01 Epub Date: 2026-10-17 DOI:10.1016/j.vhri.2026.101711

Shuiqing ZHU MS, Peng Dong PhD, Maria Gheorghe PhD, Mónica Sofia Inês PhD, Hae Kyung Kim PhD, Joseph C. Cappelleri PhD, Haitao Chu PhD, MD, Tommy Lan MSc, Kristina B. Lindsley PhD, Devon J. Boyne PhD

引用次数: 0

查看原文本刊更多论文

在先前接受按需治疗的a / b血友病患者中，马西他单抗与菲图西兰抗凝血酶剂量方案的Co11间接治疗比较

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

2.60

自引率

5.00%

发文量

127